|
|
|
|
| The oligo manufacturing landscape is evolving. Long dependent on solvent-intensive solid-phase synthesis, siRNA developers and CDMOs are beginning a critical shift toward enzymatic production—starting with enzymatic ligation. This session explores the current state of enzymatic ligation, highlighting recent advancements and the key challenges of integrating it into existing manufacturing processes. Registration is free! |
|
|
|
In Vivo's Biggest Threat — Comparison To Old Models | By Arnaud Deladeriere, Ph.D., Cell&Gene Consulting Inc. | In vivo CAR-T is not simply ex vivo without a manufacturing step. It is a different modality that relies on biological systems to regulate outcomes. In this discussion, the functions of in vivo and ex vivo enmesh to show how their designs complement each other. |
|
|
How Modality Maturity, Delivery, And Data Will Reshape RNA Therapeutics | By Deborah Day Barbara | As RNA therapeutics mature, 2026 will reward execution over novelty. Delivery, data-driven design, and modality specialization will determine which RNA platforms scale clinically and commercially. With modalities diversifying and data collection more accessible, evidenced-informed decision making is crucial to navigate industry changes. |
|
|
|
By Anna Rose Welch, Advancing RNA | Welcome to Advancing RNA's first episode of mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist. Experts Sophia Lugo and Michelle Lynn Hall discuss the biggest mistakes in building an mRNA therapeutics company, and much, much more. | |
|
|
|
| Scaling Biologic Batch Size And Reducing Cycle Times | Case Study | Jubilant HollisterStier | Partnering to optimize production can increase output by 50%. See how one global pharma lead reduced batch release times by 30% through strategic process improvements and efficiency. |
|
|
| How to De-Risk Your mRNA Regulatory Approvals | Infographic | MilliporeSigma | Reduce mRNA regulatory risk with robust quality attribute characterization. Discover how precise lot release testing ensures compliance and smoother pathways for your therapeutic candidates. |
|
|
| Improve mRNA Quality with High-Performance Polymerases | Poster | By Maite Arrizubieta, Patrik Engström, Shawn Walsh, et al., Primrose Bio | Optimized RNA polymerases enhance transcript integrity and yield. Increase capping efficiency and reduce double-stranded RNA impurities to advance your mRNA therapeutic development. |
|
|
| A New Center For Continuous mRNA Manufacturing | Article | Recipharm Advanced Bio | A unique partnership between academia and industry is reshaping mRNA production. Explore how continuous manufacturing frameworks can revolutionize the distribution of global therapies. |
|
|
|
|
| Peptides and oligonucleotides are now core to modern pipelines. | Peptides & Oligonucleotides 2026, part of NextGen Biomed, delivers practical strategies for design, chemistry, delivery, and regulatory progress. Hear from 200+ speakers to explore AI-enabled molecular design and scalable development. Plus, join our Comedy Night with Simon Brodkin. London | 24–25 March 2026 | Join us. |
|
|
|
|
|
|
.png){kind=logo}
